Opendoor (OPEN) is ringing in its “next chapter” the way Wall Street likes it best: with a leadership reshuffle that promises discipline on the numbers and ambition on the product roadmap, all while winking at the market that it still intends to…
Wall Street spent Monday looking like a market that wanted a holiday party but got a planning meeting instead, with all four major benchmarks drifting lower as investors waited on a dense week of data and central-bank choreography. The S&P 500 slipped…
Mustafa Suleyman reportedly says artificial intelligence is already superhuman, which is the sort of line that used to belong in science fiction and now lands somewhere between an earnings call remark and a lifestyle choice. Coming from the man running Microsoft’s (MSFT)…
Wall Street limped into the weekend looking like a marathoner who realized the finish line had quietly moved 100 yards farther away: still standing, but with the AI high-fliers suddenly short of breath and old‑economy cyclicals enjoying a late‑season second wind.
Indexes:…
Planet Labs (NYSE: PL) just delivered the kind of quarter that makes even jaded space investors sit up straighter, with revenue blasting past expectations and guidance pointing to a company finally acting like a real business instead of a science project in…
Wall Street ended Thursday with the Dow and S&P 500 looking like they’d just discovered compound interest, while the Nasdaq nursed an AI hangover and small caps quietly joined the advance. The Dow Jones Industrial Average surged about 1.3% to a fresh…
In a season when most micro-cap CEOs are more focused on keeping the lights on than rewriting the diabetes playbook, Modular Medical (MODD) is trying to do both – and pass the hat on Wall Street at the same time. The San…
Eli Lilly’s (LLY) latest obesity drug did not just clear the bar set by its own blockbuster Zepbound; it appears to have moved the bar, the stadium, and possibly the concession stand.
A new heavyweight in weight loss
In a late-stage trial,…
Markets leaned into the Fed’s latest cut with the kind of cautious enthusiasm usually reserved for a long‑overdue bonus.
Major indexes
U.S. stocks spent Wednesday strutting rather than sprinting, as the S&P 500 rose about 0.7% to roughly 6,887, just shy of…
GeoVax’s (NASDAQ: GOVX) latest boardroom move reads like a biotech who’s-who casting call, with the Atlanta-based vaccine developer quietly assembling a scientific brain trust that looks less like a small-cap advisory board and more like a Davos side panel on immunology.
A…